Biotechnical Faculty, Department of Animal Science, University of Ljubljana, Ljubljana, Slovenia.
Laboratory of Medical Genetics, University Medical Centre Maribor, Maribor, Slovenia.
PLoS One. 2023 May 11;18(5):e0273957. doi: 10.1371/journal.pone.0273957. eCollection 2023.
Gene- burden analyses have lately become a very successful way for the identification of genes carrying risk variants underlying the analysed disease. This approach is also suitable for complex disorders like autism spectrum disorder (ASD). The gene-burden analysis using Testing Rare Variants with Public Data (TRAPD) software was conducted on whole exome sequencing data of Slovenian patients with ASD to determine potentially novel disease risk variants in known ASD-associated genes as well as in others. To choose the right control group for testing, principal component analysis based on the 1000 Genomes and ASD cohort samples was conducted. The subsequent protein structure and ligand binding analysis usingI-TASSER package were performed to detect changes in protein structure and ligand binding to determine a potential pathogenic consequence of observed mutation. The obtained results demonstrate an association of two variants-p.Glu198Lys (PPP2R5D:c.592G>A) and p.Arg253Gln (PPP2R5D:c.758G>A) with the ASD. Substitution p.Glu198Lys (PPP2R5D:c.592G>A) is a variant, previously described as pathogenic in association with ASD combined with intellectual disability, whereas p.Arg253Gln (PPP2R5D:c.758G>A) has not been described as an ASD-associated pathogenic variant yet. The results indicate that the filtering process was suitable and could be used in the future for detection of novel pathogenic variants when analysing groups of ASD patients.
基因负担分析最近已成为鉴定分析疾病相关风险变异体所携带基因的一种非常成功的方法。这种方法也适用于自闭症谱系障碍(ASD)等复杂疾病。使用 Testing Rare Variants with Public Data (TRAPD) 软件对斯洛文尼亚 ASD 患者的外显子组测序数据进行了基因负担分析,以确定已知 ASD 相关基因以及其他基因中潜在的新疾病风险变异体。为了选择合适的测试对照组,进行了基于 1000 基因组和 ASD 队列样本的主成分分析。随后使用 I-TASSER 软件进行了蛋白质结构和配体结合分析,以检测蛋白质结构和配体结合的变化,从而确定观察到的突变的潜在致病后果。研究结果表明,两个变体 p.Glu198Lys (PPP2R5D:c.592G>A) 和 p.Arg253Gln (PPP2R5D:c.758G>A) 与 ASD 相关。取代 p.Glu198Lys (PPP2R5D:c.592G>A) 是一种变体,先前与 ASD 合并智力障碍相关被描述为致病性,而 p.Arg253Gln (PPP2R5D:c.758G>A) 尚未被描述为与 ASD 相关的致病性变体。结果表明,过滤过程是合适的,将来在分析 ASD 患者组时,可以用于检测新的致病性变体。